UOC
DNLI icon

UBS O'Connor’s Denali Therapeutics DNLI Stock Holding History

UBS O'Connor’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-21,039
Closed -$429K – 373
2024
Q4 		$429K Sell
21,039
-9,705
-32% -$248K 0.01% 295
2024
Q3 		$896K Sell
30,744
-773
-2% -$19.2K 0.02% 294
2024
Q2 		$732K Buy
31,517
+6,484
+26% +$124K 0.02% 337
2024
Q1 		$514K Sell
25,033
-9,431
-27% -$177K 0.01% 333
2023
Q4 		$740K Sell
34,464
-24,488
-42% -$485K 0.02% 306
2023
Q3 		$1.22M Buy
58,952
+10,000
+20% +$254K 0.02% 310
2023
Q2 		$1.44M Buy
+48,952
New +$1.38M 0.03% 343
2020
Q2 		– Sell
-37,200
Closed -$651K – 403
2020
Q1 		$651K Buy
+37,200
New +$776K 0.01% 250

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

UBS O'Connor's DNLI Position: Q1 2025 in Review

UBS O'Connor sold out of Denali Therapeutics (DNLI) in Q1 2025, closing a stake of 21,039 shares — an estimated $429K sold.

UBS O'Connor first reported a position in DNLI in Q1 2020 and held it in 8 quarters. The position peaked at $1.44M in Q2 2023. 222 funds tracked by Wall St. Rank hold DNLI as of Q1 2025.

  • UBS O'Connor reported no remaining Denali Therapeutics position as of Q1 2025 after selling out during the quarter.
  • UBS O'Connor sold 21,039 Denali Therapeutics shares in Q1 2025, an estimated $429K.
  • UBS O'Connor first reported a position in Denali Therapeutics in Q1 2020 and held it in 8 quarters.
  • UBS O'Connor's Denali Therapeutics position peaked at $1.44M in Q2 2023.
  • 222 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2025.

Based on UBS O'Connor's 13F filing for Q1 2025, filed 15 May 2025.